Category:

With the novel coronavirus continuing its global spread and a second wave threatening the United States later this year, experts worry an influx of influenza patients and COVID-19 patients will hit U.S. hospitals at the same time...pharma's working to ramp up not only for the increased demand but also for the logistical challenges of vaccinating millions of people during a pandemic...Manufacturers distributed about 170 million flu vaccine doses to the U.S. last year. This year, they're aiming to increase that by about 20 million...Vaccine makers are already producing their doses, with plans to start shipping later this summer...READ MORE

Neil Ferguson is the British academic who created the infamous Imperial College model that warned Boris Johnson that, without an immediate lockdown, the coronavirus would cause 500,000 deaths and swamp the National Health Service...Johnson’s government promptly abandoned its Sweden-like “social distancing” approach, and Ferguson’s model also influenced the U.S. to make lockdown moves with its shocking prediction of over two million Americans dead...Johan Giesecke, the former chief scientist for the European Center for Disease Control and Prevention, has called Ferguson’s model “the most influential scientific paper” in memory. He also says it was, sadly, “one of the most wrong.”...Ferguson has been wrong so often that some of his fellow modelers call him “The Master of Disaster.”...READ MORE

Not wanting to be left behind in the COVID-19 vaccine race, Europe is stepping up its efforts to secure supplies should any immunizations prove safe and effective. Right on the heels of news that the U.S. has picked vaccine finalists to fast-track, Europe is considering negotiations with pharmaceutical companies for early acces..The European Union has asked member countries for the power to negotiate development and access deals with drugmakers.. if the mandate were approved, Europe would base its program on the U.S.’ Biomedical Advanced Research and Development Authority...READ MORE

With the COVID-19 pandemic shining a spotlight on the global pharmaceutical supply chain, U.S. legislators have put forward a raft of legislation that would seek to "onshore" drug manufacturing at the expense of major producers abroad...Guess who's wary of that proposal? Big Pharma...the White House is reportedly working on a "Buy American" executive order that would require government agencies to purchase American-made medical products, and that order could eventually include pharmaceuticals...the Pharmaceutical Research and Manufacturers of America...has pushed back against Congressional support for a supply chain shake-up...Manufacturing stateside would likely cost a princely sum compared with the cheaper wages and lower costs abroad, and would upset the balance of pharma's global supply chain..."While we support efforts to foster more manufacturing in the United States, moving all manufacturing here is impractical and likely not feasible," a PhRMA spokesperson said in an email. "Policymakers must take a long-term, more holistic look at global pharmaceutical manufacturing supply chains before jumping to rash proposals that may cause significant disruptions to the U.S. supply of medicines."...READ MORE

...the U.S. government has shelled out big money for a stable and reliable supply of key drugs made on U.S. soil. For drugmakers accustomed to offshore manufacturing in cheaper countries, does it make any sense to onshore production to meet U.S. demand?...One company has a compelling argument, and it's taking big risks—and government funding—to test its hypothesis...Paratek Pharmaceuticals, maker of antibiotic Nuzyra, is kick-starting a three-year plan to build a government-funded, second supply chain in the U.S. in an effort to flesh out the nation's strategic supply of pandemic response drugs...The U.S. government, through its Biomedical Advanced Research and Development Authority, has dumped more than $300 million combined into helping Paratek build the U.S. supply line, which will stand apart from its current manufacturing network in Europe...READ MORE

The U.S. biopharmaceutical industry depends on reliable intellectual property protections to promote the development of new treatments and cures for patients. Strong IP protections are especially important as innovators work around the clock making substantial investments at risk to develop solutions to help prevent infection and treat those with COVID-19...many of the existing medicines and investigational medicines in clinical trials for COVID-19 exist today because of IP and other incentives that drove their initial research...Strong and reliable IP protections support America’s robust innovation ecosystem by promoting innovation and affordability for patients who rely on new treatments and cures...READ MORE

A vaccine summit has raised billions of dollars to immunize children in developing countries as experts wrestled with how any potential vaccine against the coronavirus might be distributed globally — and fairly...The United Nations and the International Red Cross and Red Crescent Movement have urged that “a people’s vaccine” be developed for COVID-19 that would be freely available to everyone, calling it a “moral imperative.”...GAVI also announced a new “advance market commitment” mechanism to enable developing countries to get any effective COVID-19 vaccine when available...READ MORE

Europe wants to be master of its own destiny in producing essential drugs and finding COVID-19 treatments, but it’s got a problem. It relies on the United States for a critical ingredient: blood plasma...As global mistrust deepens, European Union officials are casting around for ways to reduce the bloc’s dependence on American plasma...now widely applied in COVID-19 experimental therapies...The coronavirus crisis should push authorities to overhaul Europe’s blood donation system...The United States’ steadier plasma supplies are partly due to its system of paying people to donate blood used to develop medicines. In most European countries, donations are unpaid because of safety and ethical reasons...The PPTA (Plasma Protein Therapeutics Association ) drugmakers body sees a strategy based on unpaid blood donations as counterproductive. It pointed to Germany, the largest collector of plasma in Europe, as one of the few countries that compensate blood donors...READ MORE

The coronavirus pandemic hasn't deterred investors of Atlas Venture, a biotechnology-focused venture capital firm. On Friday, Atlas announced its latest fund, which opened at the end of March, had closed with a higher-than-expected yield of $400 million...Atlas initially wanted to bring in $350 million from the fund...But when the firm went out to fundraise, it was met with more than $1 billion in demand, which then pushed the fund toward a cap of $400 million...the fresh money will be put into about 15 companies, and that his firm remains interested in areas such as targeted cancer drugs, gene therapy and the central nervous system...The pandemic's impact on biotech stocks was fleeting compared to the larger market. Venture-backed drug companies have also continued to go public, which has kept firms and their investors optimistic about their ability to earn returns...While there are enormous parts of the broader economy...that have been really adversely affected by the COVID-related lockdowns, biotech is doing very well...The fund flows are very strong by any measure...READ MORE

...the first large, high-quality study to test it in people in close contact with someone with the disease...Results published...by the New England Journal of Medicine show that hydroxychloroquine was no better than placebo pills at preventing illness from the coronavirus...The study enrolled people through the Internet and social media, relying on them to report their own symptoms rather than having them tracked in a formal way by doctors. Participants were not all tested for the coronavirus but were diagnosed as COVID-19 cases based on symptoms in many cases. And not all took their medicines as directed...READ MORE